As clinical trials grow in scope and complexity, VeraSci provides the scientific and operational clarity needed for optimal trial performance and accelerated drug development. We are a global clinical and cognitive assessment services and technology company devoted to applying rigorous standards for key endpoints in multi-site clinical trials in many different indications.
VeraSci has provided consulting, site screening, rater training and certification, translation, and data services for more than 100 clinical trials in over 40 countries. With an unwavering commitment to data integrity, our work not only supports the scientific investigation of novel therapies—we’re driving major improvements to the overall quality of clinical trials and enhancing the capacity of research to transform global healthcare. Founded in 2004 as NeuroCog Trials (NCT), VeraSci is a privately held, certified woman-owned business, headquartered in Durham, North Carolina.
Learn more at https://verascience.com/
Download the VeraSci fact sheet.
We’ve developed a suite of proprietary tools that connect the latest clinical science with groundbreaking technology, providing our clients with the most versatile, reliable, and secure eCOA Solutions available.
Pathway is a fully customizable eCOA platform designed to accommodate multiple cognitive, clinical and functional outcome measures. Pathway streamlines data collection, improves the quality of results and provides seamless and secure data transfer.
The Pathway-based BAC test battery is quick and easy to administer while preserving the human interaction of traditional neurocognitive testing that is necessary for impaired populations. The electronic BAC provides investigators with meaningful results while reducing rater and patient burden.
The Virtual Reality Functional Capacity Assessment Tool (VRFCAT)
VRFCAT is a computer-based test that simulates key instrumental activities of daily living (iADLS) in a realistic and interactive virtual environment. With demonstrated sensitivity to basic functional capacity deficits, the VRFCAT was developed to improve clinical trials by detecting functionally meaningful improvements in patients’ everyday lives. The VRFCAT has numerous advantages over conventional assessments, and meets the highest psychometric and regulatory standards, with strong support from industry sponsors, NIH and FDA as a functional co-primary outcome measure.
Clinical Trial Services
VeraSci works with sponsors to identify sites with the right experience, the right staff and the right capabilities to ensure protocol compliance and deliver high quality data. Focusing on sites with low placebo response rates and high enrollment can help get trials off to a strong start. We provide additional guidance to ensure that trials are equipped with the best sites to meet their needs.
Conclusive signal detection depends on high quality data collection. Our expert reviewers identify administration inconsistencies and provide central scoring for a wide range of clinical and cognitive assessments, with rapid turnaround that ensures a clean dataset in real time. This helps sites save time, stay engaged and stay informed about study-specific assessment procedures. The VeraSci data reviewers and scientific team are available as resources to investigators and site raters throughout the duration of a clinical trial. We also provide study teams with comprehensive site performance metrics and can swiftly identify sites that may need extra support..
Scientific and Regulatory Consulting Services
VeraSci provides unparalleled expertise in clinical and neurocognitive assessment, experimental design and data analysis. We can help you select the most scientifically valid and sensitive measures for a broad range of clinical indications.
VeraSci is equally fortified by the strong connections with the academic community, including our world-class Scientific Advisors, and ongoing productive collaborations with a wide network of academic and industry leaders in every medical discipline.
Learn more about Our Trial Services
VeraSci has provided language services for clinical trials (FDA/EMA compliant) in over 60 countries, and we employ an on-call system management to ensure coverage in the applicable time zone ensuring we are responsive to inquiries within 24 hours. We deliver robust quality assurance management through SOPs and auditing – and are GCP-certified. We have provided translation service and training videos for major pharmaceutical firms and leading CROs and have a stringent certification process for linguists. Recognized both nationally and internationally, many of our 1,500 highly skilled linguists hold advanced degrees and are experienced in all phases of clinical trials. VeraSci is a corporate member of the American Translators Association and the Diversity Alliance for Science.
Acoli • Afrikaans • Akan • Albanian • American Sign Language • Amharic • Arabic • Armenian • Assamese • Azerbaijani • Balinese • Balochi • Bambara • Basque • Belarussian • Bengali • Bhojpuri • Bosnian • Bulgarian • Burmese • Cambodian • Catalan • Cebuano • Chamorro • Chewa • Chinese – Cantonese • Chinese – Mandarin • Chuukese • Croatian • Czech • Dangme • Danish • Dari • Dinka • Dioula • Dogri • Dutch • Dzongkha • English • Estonian • Ewe • Farsi • Finnish • French – Canada • French – France • Fula • Ga • Gaelic • Galician • Ganda • Georgian • German • Greek • Greenlandic • Guarani • Gujarati • Haitian – Creole • Hakha Chin (Lai) • Hausa • Hebrew • Hiligaynon • Hindi • Hmong • Hungarian • Iban • Icelandic • Igbo • Iloko • Indonesian • Inuktitut • Italian • Japanese • Javanese • Kannada • Karen • Kashmiri • Kazakh • Kikuyu • Kinyarwanda • Kirundi • Kiswahili • Konkani • Korean • Kosovan • Kurdish • Kyrgyz • Lao • Latin • Latvian • Lingala • Lithuanian • Luxembourgish • Maay Maay • Macedonian • Madurese • Maithili • Malagasy • Malay • Malayalam • Maltese • Maninka • Marathi • Mongolian • Montenegrin • Nepali • Newar • Nigerian • Norwegian • Oriya • Oromo • Pangasinan • Pashto • Polish • Portuguese – Brazil • Portuguese – Portugal • Q’eqchi’ / Kekchi • Rajasthani • Romanian • Romansch • Russian • Sami • Samoan • Sepedi • Serbian • Sesotho • Shona • Sindhi • Slovac • Slovenian • Somali • Southern Sotho • Spanish • Sukuma • Swahili • Swedish • Sylheti • Tagalog • Taiwanese • Tajik • Tamazight • Tamil • Tatar • Telugu • Tetum • Thai • Tibetan • Tigre • Tigrinya • Tongan • Tsonga • Turkish • Twi • Ukrainian • Urdu • Uygur • Uzbek • Vietnamese • Welsh • Wolof • Xhosa • Yoruba • Zulu
Learn more about Our Language Services
Recognized as global leaders in the CNS field, we now support clinical trials in a wide variety of therapeutic areas, from Alzheimer’s disease to schizophrenia to oncology, and orphan diseases. Our network of academic consultants and clinical experts collaborate with us to make sure we are implementing the latest trial technology and utilizing the most appropriate tools.
Areas of Therapeutic Expertise
• Mild Cognitive Impairment
• Alzheimer’s Disease
• Mood Disorders (MDD/Bipolar Disorder)
• Rare and Orphan Diseases
• Restless Leg Syndrome
• Multiple Sclerosis
• Parkinson’s Disease
• Opioid Use Disorder
Learn more about Our Therapeutic Areas
Richard E. Keefe, PhD, Co-Founder and CEO
Dr. Richard Keefe co-founded NeuroCog Trials, now VeraSci, in an effort to bring transformative, scientifically rigorous innovation to neurocognitive data collection in clinical trials. He has over 25 years of experience in clinical psychology, neuroscience, and drug development, and is globally recognized for his expertise in novel strategies for measuring treatment-related changes in human performance and behavior. As Chief Executive Officer, Dr. Keefe provides leadership across our scientific, technology, operational, and quality assurance teams, and maintains supportive relationships with key industry leaders and scientific advisors. Dr. Keefe’s responsive, engaged leadership and his commitment to scientific integrity are at the core of our company culture and service model. In addition to his role at VeraSci, Dr. Keefe is Professor of Psychiatry, Psychology and Neurosciences at Duke University Medical Center, and serves on the Editorial Board of Psychological Medicine, Schizophrenia Research, and Innovations in Clinical Neuroscience. He is a Fellow of the American College of Neuropsychopharmacology, and on the Scientific Board of the Brain and Behavior Research Foundation. Dr. Keefe was President of the International Society for CNS Clinical Trials and Methodology from 2012 to 2014. He has published over 250 peer-reviewed scientific papers on cognition and CNS disorders. He received his bachelor’s degree in psychology from Princeton University and received his PhD in clinical psychology from NYU. He completed his clinical psychology internship at Yale University School of Medicine.
Caren Gadigian, Co-Founder and President
Caren Gadigian co-founded NeuroCog Trials, now VeraSci, in 2004, bringing her extensive knowledge of finance and business to spearhead the company’s successful development and rapid expansion. She has over 20 years of experience working with private equity firms, providing investment management and operational expertise across a variety of industry sectors. As President, Ms. Gadigian is responsible for leading the company’s strategic growth and directing the standard of excellence that defines all company operations. With an incisive understanding of organizational development, she ensures that VeraSci has the best staff and the most effective services to achieve the greatest impact on therapeutic discovery.
Learn more about VeraSci’s Leadership
For more information or to further discuss your study needs please contact:
Bobbie Theodore, M.S.
Alliance Executive Director